Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial-Reference-Cited by-同舟云学术

Efficacy of tamoxifen±aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial

Published:2013-03-19 Issue:7 Volume:108 Page:1408-1414
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Pfeiler G, ,Stöger H,Dubsky P,Mlineritsch B,Singer C,Balic M,Fitzal F,Moik M,Kwasny W,Selim U,Renner K,Ploner F,Steger G G,Seifert M,Hofbauer F,Sandbichler P,Samonigg H,Jakesz R,Greil R,Fesl C,Gnant M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013114.pdf

Reference20 articles.

1. Baum M, Budzar AU, Cuzick J, Salmon RJ, Fourquet A, Asselain B (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131–2139

2. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, Moore SC, Tobias GS, Anton-Culver H, Freeman LB, Beeson WL, Clipp SL (2010) Body-mass index and mortality among 1.46 million white adults. N Engl J Med 363: 2211–2219

3. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D (2010) Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet 376: 1775–1784

4. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119: 145–153

5. Després JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444: 881–887

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial;ESMO Open;2024-08

2. Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial;Journal of Clinical Oncology;2023-11-20

3. Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation;Cancer Biology & Medicine;2023-03-08

4. Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis;International Journal of Cancer;2022-10-24

5. Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives;Obesity Reviews;2021-09-24